OA12778A - Pharmaceutical combination of COX-2 inhibitors andipiates. - Google Patents

Pharmaceutical combination of COX-2 inhibitors andipiates. Download PDF

Info

Publication number: OA12778A
Authority: OA; OAPI
Prior art keywords: combination; daim; codeine; pharmaceutical composition; pharmaceutically acceptable
Prior art date: 2002-02-19

Application number

OA1200400220A

Other languages

English (en)

Inventor

Michael Christian Norris

Original Assignee

Adcock Ingram Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-19

Filing date

2003-02-14

Publication date

2006-07-06

2003-02-14 Application filed by Adcock Ingram Ltd filed Critical Adcock Ingram Ltd

2006-07-06 Publication of OA12778A publication Critical patent/OA12778A/en

Links

229940111134 coxibs Drugs 0.000 title claims abstract description 12
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims abstract description 12
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims abstract description 100
229960004126 codeine Drugs 0.000 claims abstract description 50
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims abstract description 50
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims abstract description 49
229960001929 meloxicam Drugs 0.000 claims abstract description 49
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 46
208000002193 Pain Diseases 0.000 claims abstract description 26
230000036407 pain Effects 0.000 claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
229940127240 opiate Drugs 0.000 claims abstract description 12
239000002599 prostaglandin synthase inhibitor Substances 0.000 claims abstract description 12
206010037660 Pyrexia Diseases 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 9
229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims abstract description 8
206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 5
206010061218 Inflammation Diseases 0.000 claims abstract description 5
208000000112 Myalgia Diseases 0.000 claims abstract description 5
230000000307 algesic effect Effects 0.000 claims abstract description 5
230000004054 inflammatory process Effects 0.000 claims abstract description 5
208000014674 injury Diseases 0.000 claims abstract description 4
201000008482 osteoarthritis Diseases 0.000 claims abstract description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 4
230000008733 trauma Effects 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 11
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 9
229960004380 tramadol Drugs 0.000 claims description 9
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 9
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 4
229960000590 celecoxib Drugs 0.000 claims description 3
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 3
229960005181 morphine Drugs 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
101150071146 COX2 gene Proteins 0.000 claims description 2
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims description 2
101150000187 PTGS2 gene Proteins 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229960000371 rofecoxib Drugs 0.000 claims description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 10
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
229960002428 fentanyl Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 abstract description 5
229960005489 paracetamol Drugs 0.000 abstract description 3
239000004480 active ingredient Substances 0.000 abstract 1
230000000917 hyperalgesic effect Effects 0.000 abstract 1
241000700159 Rattus Species 0.000 description 32
239000003795 chemical substances by application Substances 0.000 description 28
230000003070 anti-hyperalgesia Effects 0.000 description 26
230000000694 effects Effects 0.000 description 21
238000012360 testing method Methods 0.000 description 17
208000028867 ischemia Diseases 0.000 description 13
208000004454 Hyperalgesia Diseases 0.000 description 9
208000035154 Hyperesthesia Diseases 0.000 description 9
230000010410 reperfusion Effects 0.000 description 7
230000002411 adverse Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
230000036592 analgesia Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000001473 noxious effect Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 4
235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 4
230000003502 anti-nociceptive effect Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
229960004415 codeine phosphate Drugs 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
230000020341 sensory perception of pain Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920001800 Shellac Polymers 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
235000019486 Sunflower oil Nutrition 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000004208 shellac Substances 0.000 description 3
229940113147 shellac Drugs 0.000 description 3
235000013874 shellac Nutrition 0.000 description 3
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000002600 sunflower oil Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000001754 anti-pyretic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003925 brain function Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
-1 for example Substances 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
238000007689 inspection Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000008447 perception Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000000837 restrainer Substances 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
BYACHAOCSIPLCM-UHFFFAOYSA-N 2-[2-[bis(2-hydroxyethyl)amino]ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCN(CCO)CCO BYACHAOCSIPLCM-UHFFFAOYSA-N 0.000 description 1
229940124638 COX inhibitor Drugs 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
238000001135 Friedman test Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
101100168274 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-3 gene Proteins 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003965 antinociceptive agent Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229940092738 beeswax Drugs 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
230000006397 emotional response Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000036449 good health Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
208000020442 loss of weight Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200400220A 2002-02-19 2003-02-14 Pharmaceutical combination of COX-2 inhibitors andipiates. OA12778A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ZA200201395		2002-02-19

Publications (1)

Publication Number	Publication Date
OA12778A true OA12778A (en)	2006-07-06

Family

ID=27758232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400220A OA12778A (en)	2002-02-19	2003-02-14	Pharmaceutical combination of COX-2 inhibitors andipiates.

Country Status (20)

Country	Link
US (1)	US20050090517A1 (de)
EP (2)	EP2050453B1 (de)
JP (1)	JP2005519936A (de)
CN (1)	CN100418533C (de)
AP (1)	AP1862A (de)
AT (2)	ATE524186T1 (de)
AU (1)	AU2003208485B2 (de)
CA (1)	CA2476939C (de)
CY (1)	CY1108839T1 (de)
DE (1)	DE60325020D1 (de)
DK (1)	DK1478366T3 (de)
EG (1)	EG24845A (de)
ES (2)	ES2376500T3 (de)
IL (2)	IL163637A0 (de)
NZ (1)	NZ535500A (de)
OA (1)	OA12778A (de)
PT (2)	PT1478366E (de)
SI (1)	SI1478366T1 (de)
WO (1)	WO2003070251A1 (de)
ZA (1)	ZA200407485B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007530620A (ja) *	2004-04-01	2007-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	メロキシカムを含む組成物
JP2008501655A (ja) *	2004-06-04	2008-01-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	メロキシカム含有組成物
ITMI20060983A1 (it) *	2006-05-18	2007-11-19	Formevet S P A	Composizioni farmaceutiche veterinarie per il trattamento del dolore e dell'inifiamazione
WO2007138466A2 (en) *	2006-06-01	2007-12-06	Wockhardt Ltd	Pharmaceutical compositions comprising meloxicam and tramadol combination
US20080031950A1 (en) *	2007-04-27	2008-02-07	Nectid Inc.	Novel anelgesic combination
US20080026054A1 (en) *	2007-04-27	2008-01-31	Nectid Inc.	Novel anelgesic combination
EP2177215A1 (de)	2008-10-17	2010-04-21	Laboratorios Del. Dr. Esteve, S.A.	Co-Kristalle von Tramadol und NSARs
EP2311446A1 (de) *	2009-10-16	2011-04-20	Laboratorios Del. Dr. Esteve, S.A.	Zusammensetzungen, die Tramadol und Celecoxib umfassen, zur Behandlung von Schmerzen
IT1398321B1 (it) *	2010-02-26	2013-02-22	Formevet Spa Ora Formevet Srl	Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario
EP2392319A1 (de) *	2010-06-04	2011-12-07	Laboratorios Del. Dr. Esteve, S.A.	Pharmazeutische Zusammensetzung enthaltend Cokristalle aus Tramadol und einem Coxib
WO2015004505A1 (es) *	2013-07-11	2015-01-15	More Pharma Corporation, S. De R.L. De C.V.	Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2018013070A (es)	2017-12-29	2019-10-15	Gruenenthal Gmbh	Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
US20210346328A1 (en) *	2018-09-21	2021-11-11	The Johns Hopkins University	Compositions and methods for treating metabolic disorders
CN115300515A (zh) *	2022-08-11	2022-11-08	南京红地生物科技有限公司	一种含有美洛昔康和盐酸曲马多的长效注射液

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA845785B (en) *	1983-06-10	1985-03-27	Adcock Ingram Lab Ltd	Pharmaceutical unit
ZA893422B (en) *	1988-02-24	1991-01-30	Adcock Ingram Lab Ltd	Pharmaceutical composition
AU3990895A (en) *	1995-12-05	1997-06-27	Adcock Ingram Limited	Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
RS49982B (sr) *	1997-09-17	2008-09-29	Euro-Celtique S.A.,	Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
FR2770131A1 (fr) *	1997-10-27	1999-04-30	Union Pharma Scient Appl	Nouvelle association pharmaceutique a activite analgesique
US6375957B1 (en) *	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
EP2266564B1 (de) *	1997-12-22	2013-03-13	Euro-Celtique S.A.	Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem opioid Agonisten und einem opioid Antagonisten
MXPA02010764A (es) *	2000-05-31	2003-03-10	Warner Lambert Co	Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
ATE511844T1 (de) *	2000-06-13	2011-06-15	Wyeth Llc	Analgetische und entzündungshemmende zusammensetzungen enthaltend celecoxib und ibuprofen

2003
- 2003-02-14 IL IL16363703A patent/IL163637A0/xx unknown
- 2003-02-14 NZ NZ535500A patent/NZ535500A/en not_active IP Right Cessation
- 2003-02-14 EP EP08170195A patent/EP2050453B1/de not_active Expired - Lifetime
- 2003-02-14 AU AU2003208485A patent/AU2003208485B2/en not_active Ceased
- 2003-02-14 WO PCT/IB2003/000500 patent/WO2003070251A1/en not_active Ceased
- 2003-02-14 US US10/505,291 patent/US20050090517A1/en not_active Abandoned
- 2003-02-14 ES ES08170195T patent/ES2376500T3/es not_active Expired - Lifetime
- 2003-02-14 PT PT03706774T patent/PT1478366E/pt unknown
- 2003-02-14 JP JP2003569207A patent/JP2005519936A/ja active Pending
- 2003-02-14 ES ES03706774T patent/ES2318113T3/es not_active Expired - Lifetime
- 2003-02-14 OA OA1200400220A patent/OA12778A/en unknown
- 2003-02-14 CA CA2476939A patent/CA2476939C/en not_active Expired - Lifetime
- 2003-02-14 SI SI200331530T patent/SI1478366T1/sl unknown
- 2003-02-14 PT PT08170195T patent/PT2050453E/pt unknown
- 2003-02-14 CN CNB038085321A patent/CN100418533C/zh not_active Expired - Fee Related
- 2003-02-14 AT AT08170195T patent/ATE524186T1/de not_active IP Right Cessation
- 2003-02-14 AT AT03706774T patent/ATE415971T1/de active
- 2003-02-14 EP EP03706774A patent/EP1478366B1/de not_active Expired - Lifetime
- 2003-02-14 DK DK03706774T patent/DK1478366T3/da active
- 2003-02-14 AP APAP/P/2004/003134A patent/AP1862A/en active
- 2003-02-14 DE DE60325020T patent/DE60325020D1/de not_active Expired - Lifetime
2004
- 2004-08-19 IL IL163637A patent/IL163637A/en active IP Right Grant
- 2004-08-19 EG EGNA2004000074 patent/EG24845A/xx active
- 2004-09-17 ZA ZA2004/07485A patent/ZA200407485B/en unknown
2009
- 2009-02-27 CY CY20091100239T patent/CY1108839T1/el unknown

Also Published As

Publication number	Publication date
NZ535500A (en)	2006-09-29
CA2476939C (en)	2012-08-28
ES2376500T3 (es)	2012-03-14
EP2050453A1 (de)	2009-04-22
AU2003208485B2 (en)	2009-05-28
US20050090517A1 (en)	2005-04-28
CN1646133A (zh)	2005-07-27
JP2005519936A (ja)	2005-07-07
AU2003208485A1 (en)	2003-09-09
IL163637A0 (en)	2005-12-18
WO2003070251A1 (en)	2003-08-28
EG24845A (en)	2010-10-21
DK1478366T3 (da)	2009-03-30
AP2004003134A0 (en)	2004-09-30
PT2050453E (pt)	2012-01-03
AP1862A (en)	2008-07-07
CY1108839T1 (el)	2014-07-02
DE60325020D1 (de)	2009-01-15
EP2050453B1 (de)	2011-09-14
ES2318113T3 (es)	2009-05-01
IL163637A (en)	2010-11-30
EP1478366B1 (de)	2008-12-03
CN100418533C (zh)	2008-09-17
CA2476939A1 (en)	2003-08-28
ZA200407485B (en)	2005-12-28
ATE524186T1 (de)	2011-09-15
PT1478366E (pt)	2009-03-10
EP1478366A1 (de)	2004-11-24
ATE415971T1 (de)	2008-12-15
SI1478366T1 (sl)	2009-06-30

Publication	Publication Date	Title
OA12778A (en)	2006-07-06	Pharmaceutical combination of COX-2 inhibitors andipiates.
Moore	2020	Coronary risks associated with diclofenac and other NSAIDs: an update
Lázaro-Ibáñez et al.	2001	Participation of the nitric oxide–cyclic GMP–ATP-sensitive K+ channel pathway in the antinociceptive action of ketorolac
Mehlisch	2002	The efficacy of combination analgesic therapy in relieving dental pain
Keyhanfar et al.	2013	Evaluation of antinociceptive effect of pregabalin in mice and its combination with tramadol using tail flick test
Onuţu	2015	Duloxetine, an antidepressant with analgesic properties–a preliminary analysis
Mehlisch et al.	2003	Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery
Miranda et al.	2005	Spinal synergy between nonselective cyclooxygenase inhibitors and morphine antinociception in mice
Rasmussen	2005	Treatment of elevated intracranial pressure with indomethacin: friend or foe?
Granados-Soto et al.	1999	A review of the pharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-inflammatory drugs by caffeine
Moreno-Rocha et al.	2012	Antinociceptive effects of tramadol in co-administration with metamizol after single and repeated administrations in rats
Arnstein	2010	Balancing analgesic efficacy with safety concerns in the older patient
Lui et al.	2004	Preemptive effects of intrathecal cyclooxygenase inhibitor or nitric oxide synthase inhibitor on thermal hypersensitivity following peripheral nerve injury
Miranda et al.	2004	Isobolographic analysis of the antinociceptive interactions of clonidine with nonsteroidal anti-inflammatory drugs
Pappagallo	1999	Aggressive pharmacologic treatment of pain
Sartini et al.	2008	Open experience with a new myorelaxant agent for low back pain
Kelkar et al.	2001	Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Aguirre-Bañuelos et al.	1999	Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia
Brown-Croyts et al.	2000	Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning
BR0317950A (pt)	2005-11-29	Inibidores de quinurrenina 3-hidroxilase para o tratamento de diabetes por aumento do número de ilhotas de células de langerhans
Parronchi	2004	Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients
HK1126400A (en)	2009-09-04	Pharmaceutical combinations of meloxicam, tramadol and paracetamol
Salinska et al.	2008	Dantrolene antagonizes the glycineB site of the NMDA receptor
Fruhwald et al.	2004	Differential reversal of drug-induced small bowel paralysis by cerulein and neostigmine
Puolakka	2011	Some challenges of postoperative pain treatment